Skip to main content


Eurofins Viracor BioPharma is a unique clinical development partner with proven expertise in custom assay design and validation across a broad array of industry-leading analytical platforms.  We partner with our clients to support their oncology-focused translational research with innovative technologies and integrated testing solutions that provide the flexibility and scalability to help advance their pioneering treatments to market faster.


Molecular & genomics bioassay capabilities for clinical immunotherapy studies:

  • Predictive biomarker assays (whole exome or RNA sequencing)
  • qPCR or microarray-based RNA expression assays
  • Gene expression profiles for detecting and characterizing mutations/biomarkers in cancer cells with Nanostring technology.
  • Comprehensive targeted NGS panels or tumor profiling assays to detect known and emerging biomarkers, and measure tumor mutational burden

We also offers a comprehensive and diverse technology portfolio, together with in-house expertise, to provide custom assay design, validation, and analysis for any supported platform including:

  • PCR, ddPCR, Sanger
  • NGS (WGS, WES, RNASeq, somatic testing, and custom panels
  • Nanostring (non-PCR gene  expression)
  • Flow Cytometry

Eurofins Viracor Biopharma


You’re blazing a new path in the immuno-oncology drug development frontier. You need a partner who understands the complexity of biomarker research to develop and perform critical assays that help keep you moving toward market success. Eurofins Viracor Biopharma has over thirty-five years of experience supporting clinical research.




There are many complexities that make cell and gene therapy development challenging. It is crucial that the new gene reaches the correct cell without causing an unintended immune response.

Click here to view our Cell & Gene Therapy brochure and learn more about the services we offer to support the development of novel cell and gene therapies.



Our new NGS assay enables comprehensive genomic profiling of solid tumor samples and liquid (plasma) biopsies.

Learn More

Back to top